Published in final edited form as:

Med Care. 2017 December ; 55(12): 1030–1038. doi:10.1097/MLR.0000000000000822.

Regional Medicare Expenditures and Survival among Older Women with Localized Breast Cancer

Sara Tannenbaum, BA^{*}, Pamela R. Soulos, MPH^{†,‡}, Jeph Herrin, PhD^{‡,§,||}, Sarah Mougalian, MD^{‡,||}, Jessica B. Long, MPH^{†,‡}, Rong Wang, PhD^{‡,§}, Xiaomei Ma, PhD^{‡,§}, Cary P. Gross, MD^{†,‡}, and Xiao Xu, PhD^{‡,§}

^{*}Yale School of Medicine, New Haven, CT

[†]Section of General Internal Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT

[‡]Yale University Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center, New Haven, CT

[§]Division of Cardiology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT

^{||}Health Research & Educational Trust, Chicago, IL

Corresponding Author and Request for Reprints: Xiao Xu, PhD, Department of Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine, 310 Cedar Street, LSOG 205B, New Haven, CT 06520; Phone: 203-737-6254; xiao.xu@yale.edu.

Complete Author Information:

Sara Tannenbaum, BA, Yale School of Medicine, New Haven, CT 06520; Phone: 847-312-1526; Fax: N/A; sara.tannenbaum@yale.edu

Pamela R. Soulos, MPH, Section of General Internal Medicine, Department of Internal Medicine, Yale School of Medicine; Yale Cancer Outcomes, Public Policy and Effectiveness Research Center; 367 Cedar Street, Harkness A Rm 418A, New Haven, CT 06520; Phone: 203-737-4651; Fax: 203-737-3306; pamela.soulos@yale.edu

Jeph Herrin, PhD, Division of Cardiology, Department of Internal Medicine, Yale School of Medicine; Yale Cancer Outcomes, Public Policy and Effectiveness Research Center; 15 York Street, FMP 3, PO BOX 208017, New Haven, CT 06520; Health Research & Educational Trust, Chicago IL; Phone: 434-295-5342; Fax: 509-471-5158; jeph.herrin@yale.edu

Sarah Mougalian, MD, Section of Medical Oncology, Department of Internal Medicine, Yale School of Medicine; Yale Cancer Outcomes, Public Policy and Effectiveness Research Center; 25 York Street, PO BOX 208028, New Haven, CT 06520; Phone: 203-785-4022; Fax 203-785-5792; sarah.mougalian@yale.edu

Jessica B. Long, MPH, Section of General Internal Medicine, Department of Internal Medicine, Yale School of Medicine; Yale Cancer Outcomes, Public Policy and Effectiveness Research Center; 367 Cedar Street, PO BOX 208093, New Haven, CT 06520; Phone: 276-632-0954; Fax: N/A; jessica.long@yale.edu

Rong Wang, PhD, Department of Chronic Disease Epidemiology, Yale University School of Public Health; Yale Cancer Outcomes, Public Policy and Effectiveness Research Center; 55 Church Street, Ste 801, PO BOX 208034, New Haven, CT 06520; Phone: 203-764-7043; Fax: 203-785-6980; r.wang@yale.edu

Xiaomei Ma, PhD, Department of Chronic Disease Epidemiology, Yale University School of Public Health; Yale Cancer Outcomes, Public Policy and Effectiveness Research Center; 60 College Street, LEPH 406, PO Box 208034, New Haven, CT 06520; Phone: 203-785-3880; Fax: 203-785-6980; xiaomei.ma@yale.edu

Cary P. Gross, MD, Section of General Internal Medicine, Department of Internal Medicine, Yale University School of Medicine; Yale Cancer Outcomes, Public Policy and Effectiveness Research Center; 367 Cedar Street, Harkness Office Rm 412A, PO BOX 208093, New Haven, CT 06520; Phone: 203-688-8075; Fax: 203-737-7524; cary.gross@yale.edu

Xiao Xu, PhD, Department of Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine; Yale Cancer Outcomes, Public Policy and Effectiveness Research Center; 310 Cedar Street, LSOG 205B, PO Box 208063, New Haven, CT 06520; Phone: 203-737-6254; Fax: 203-785-6586; xiao.xu@yale.edu

Disclosure of Potential Conflicts of Interest: Dr. Gross and Ms. Soulos receive research funding from 21st Century Oncology LLC. Dr. Gross has also received funding from Medtronic and Johnson & Johnson and from the National Comprehensive Cancer Network-Pfizer. Dr. Ma consulted for Celgene and Incyte. Dr. Mougalian receives consulting fees from HylaPharm LLC and Eisai Pharmaceuticals, and she receives research funding from Pfizer through a joint NCCN-Pfizer research grant. Sara Tannenbaum, Jeph Herrin, Jessica Long, Rong Wang, and Xiao Xu have no disclosures.

¶Section of Medical Oncology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT

#Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT

**Department of Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine, New Haven, CT

Abstract

Background—Despite evidence on large variation in breast cancer expenditures across geographic regions, there is little understanding about the association between expenditures and patient outcomes.

Objectives—To examine whether Medicare beneficiaries with non-metastatic breast cancer living in regions with higher cancer-related expenditures had better survival.

Research Design—A retrospective cohort study of women with localized breast cancer from the Surveillance, Epidemiology and End Results-Medicare linked database. Hospital referral regions (HRR) were categorized into quintiles based on risk-standardized per patient Medicare expenditures on initial phase of breast cancer care. Hierarchical generalized linear models were estimated to examine the association between patients' HRR quintile and survival.

Subjects—12,610 Medicare beneficiaries diagnosed with stage II–III breast cancer during 2005–2008 who underwent surgery.

Measures—3-year and 5-year overall survival.

Results—Risk-standardized per patient Medicare expenditures on initial phase of breast cancer care ranged from \$13,338 to \$26,831 across the HRRs. Unadjusted 3-year and 5-year survival varied from 66.7% to 92.2% and 50.0% to 84.0%, respectively, across the HRRs, but there was no significant association between HRR quintile and survival in bivariate analysis ($P=.08$ and $.28$, respectively). After adjustment for sociodemographic and clinical characteristics, quintiles of regional cancer expenditures remained unassociated with patients' 3-year ($P=.35$) and 5-year survival ($P=.20$). Further analysis adjusting for treatment factors (surgery type and receipt of radiation and systemic therapy) and stratifying by cancer stage showed similar results.

Conclusions—For Medicare beneficiaries with non-metastatic breast cancer, residence in regions with higher breast cancer-related expenditures was not associated with better survival. More attention to value in breast cancer care is warranted.

Keywords

Breast cancer; expenditure; survival; regional variation

Introduction

Breast cancer is the most common malignancy in women, with almost 250,000 women diagnosed annually in the United States (US).¹ It is also the most costly cancer in the US, with total breast cancer expenditures reaching \$16.5 billion in 2010 and projected to grow to \$20.5 billion by 2020.² Increase in costs of breast cancer care over the last few decades has

been linked to improved life expectancy.^{3,4} However, comparison with European countries shows mixed evidence regarding whether the additional spending on breast cancer care in the US provides good “value” in terms of quality adjusted life years gained or people’s willingness to pay for the additional life years.^{4,5}

Costs of breast cancer care vary widely by geographic region.^{6–9} For example, among 80 hospital referral regions (HRRs) across the US, mean 6-month Medicare spending varied from \$28,854 in the lowest spending quintile to \$37,971 in the highest spending quintile for women newly diagnosed with stage IV breast cancer during 2002–2007.⁸ Similarly, mean Medicare expenditures for initial breast cancer care (2 months prior to through 12 months after diagnosis) ranged from \$15,053 to \$23,480 across HRR quintiles for women with stage I–III disease during 2005–2008.⁶ Moreover, there is evidence for substantial differences in use of breast conserving treatment and radiation therapy across regions, which may also result in variability in expenditures.^{10,11}

It has been shown that HRRs with higher overall expenditures on breast cancer care tended to utilize more resources in virtually all components of care (e.g., surgery, radiation therapy, systemic therapy), especially newer and expensive technologies such as intensity modulated radiation therapy.⁶ Given such large variation in resource utilization across geographic regions, an important question that remains largely unaddressed is whether women residing in HRRs with higher expenditures experience better outcomes. Answer to this question can inform geographic variation within the US in value of care (i.e., patient outcomes relative to cost) and help identify opportunities for delivering high-value care.

To shed light on this issue, we examined whether patients with non-metastatic breast cancer living in regions with higher breast cancer-related Medicare expenditures had increased rates of survival. We examined 3-year as well as 5-year survival while controlling for patient sociodemographic and clinical characteristics. Findings from this study can inform future discussions on value of cancer care. Ultimately, by identifying exemplary care patterns in regions with low expenditure and good outcomes, and improving care in regions with high expenditure but poor outcomes, we can enhance overall value in care.

Methods

Study Design

We conducted a retrospective cohort study of women with localized breast cancer identified from the Surveillance, Epidemiology and End Results (SEER)-Medicare linked database. A previous study estimated risk-standardized per patient Medicare expenditure on breast cancer care for HRRs in SEER registry areas.⁶ By linking these estimates to patient-level data from the SEER-Medicare dataset, we analyzed the association between risk-standardized breast cancer care expenditure of a patient’s HRR and her survival.

Data Sources and Study Sample

The SEER-Medicare dataset includes patient-level information from SEER registries, including demographic and cancer characteristics, which has been linked with Medicare claims. The geographic regions covered by SEER registries represent 28% of the US

population, and the SEER-Medicare linked database included data from States of California, Connecticut, Georgia, Hawaii, Iowa, Kentucky, Louisiana, New Jersey, New Mexico, and Utah, as well as Detroit metropolitan area and multi-county Seattle-Puget Sound area.^{12–14} Our cohort included female Medicare beneficiaries who were diagnosed with stage II–III breast cancer during 2005–2008 and underwent surgery (either lumpectomy or mastectomy) within 9 months of diagnosis. We excluded patients with stage 0, I or IV breast cancer because their survival was less amenable to differences in care given their generally good or poor prognosis.^{1,15} Patients who were previously diagnosed with any cancer (regardless of cancer site) or had a second cancer (not of the breast) any time between diagnosis through one year after surgery were also excluded. For patients who had multiple diagnoses of breast cancer during 2005–2008, only their first breast cancer diagnosis was included in analysis.

The diagnosis years selected were the most recent ones that would allow for at least 5-year follow-up, as vital status was recorded through the end of 2013. We excluded women under 67 years of age at time of diagnosis and those without continuous Medicare Parts A and B fee-for-service coverage during the 2 years before breast cancer diagnosis, so that patients in our sample had a 2-year look back period to adequately assess comorbidity status.¹⁶ Therefore, overall our sample selection and construction of measures used information from 2003–2013 SEER-Medicare data. Patients covered by Medicare advantage plans at any time during the 2-year look back period or the 12 months after diagnosis were excluded to ensure a complete record of their claims. Patients who were dually eligible for Medicaid were retained in sample.

We used beneficiary mailing zip code to assign each woman to her HRR of residence as defined by the Dartmouth Atlas,¹⁷ and then linked patient-level data to previous estimates of risk-standardized per beneficiary Medicare expenditure on initial breast cancer care by HRR.⁶ HRRs reflect regional markets for tertiary-level medical care.¹⁸ Because risk-standardized expenditures were only calculated for HRRs with at least 25 patients with breast cancer (stage I–III) in order to ensure adequate sample size for the estimate,⁶ patients in smaller HRRs (i.e., <25 patients with stage I–III breast cancer) were excluded from our cohort. The broader patient population involved in the Medicare expenditure measure (i.e., stage I–III patients) provided a more exogenous assessment of spending and allowed for a larger sample size in estimating expenditures. It served as a marker for intensity of breast cancer care in the HRR.

Measures

We obtained measures of HRR-specific, risk-standardized per patient breast cancer-related Medicare expenditures from a previous study.⁶ Detailed methods for this measure were published previously.⁶ Briefly, for each HRR, risk-standardized per patient Medicare expenditure on breast cancer care was calculated by adjusting for patient sociodemographic characteristics and health conditions and taking the difference in risk-adjusted expenditures between patients with breast cancer and matched controls while accounting for clustering in data by HRR. Health conditions adjusted for in the model included comorbidity status and tumor characteristics for patients with breast cancer and comorbidity status alone for matched controls. Medicare expenditures across all care settings (including inpatient,

physician, hospital-based outpatient, home health, durable medical equipment, and hospice care, but except Part D claims) during the initial phase of care, i.e., 2 months before through 12 months after diagnosis date (for cancer patients) or index date (for matched controls), were included. Expenditures were adjusted for differences in input prices across geographic regions and were inflation adjusted to 2009 US dollars. HRRs were categorized into quintiles based on their risk-standardized per patient Medicare expenditures on breast cancer care (quintile 1 = lowest expenditure and quintile 5 = highest expenditure). These HRR quintiles were our primary independent variable.

Outcome measures for our analysis were 3-year and 5-year overall survival. For each patient in our cohort, we measured survival status at 3 years and 5 years after diagnosis. These timeframes allowed us to reasonably capture the health impact of potentially different treatment patterns in regions with varying levels of resource utilization.

Patient-level characteristics included age at diagnosis, race (white, black or other), marital status, income quintile (based on median household income of patients' census tract or zip code), residence in a metropolitan area (yes/no), year of diagnosis, Elixhauser comorbidity score,¹⁹ disability status,²⁰ access to care (receipt of an influenza vaccine and any primary care provider visit in the year before surgery), and tumor characteristics. We assessed comorbidity for each patient using a modified Elixhauser index based on her International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes from 24 through 3 months before the diagnosis of breast cancer.¹⁹ Consistent with prior work,^{3,6} our determination of comorbidities used claims that were billed on an inpatient claim or on 2 or more outpatient/physician claims that were billed at least 30 days apart. Patients were classified as either "disabled" or "not disabled" according to a validated, claims-based disability index using information on type of medical services received over the year before diagnosis.²⁰ Tumor characteristics included stage, size, laterality, presence of a positive lymph node, hormone receptor status, and grade.

Additionally, we measured indicators of cancer treatments received, including surgery type (lumpectomy versus mastectomy), receipt of radiation therapy (yes/no), and receipt of systemic therapy (yes/no). These three treatment factors, i.e., surgery, radiation therapy, and systemic therapy, were shown to contribute the most to Medicare expenditures on initial breast cancer care.⁶ ICD-9-CM diagnosis and procedure codes, Current Procedural Terminology codes, and Healthcare Common Procedure Coding System codes were used to identify these treatments.

Statistical Analysis

We first summarized patient characteristics using descriptive statistics and assessed bivariate associations of HRR expenditure quintile and other patient characteristics with 3-year and 5-year survival using Chi square tests. We then plotted Kaplan-Meier curves to illustrate patterns of survival over time in each HRR quintile. To assess differences in outcomes, we compared survival rates at 3 years and 5 years, respectively, across HRR quintiles. We used dichotomous rather than time-to-event outcomes to improve interpretation of results. Specifically, for each endpoint (3- and 5-year survival), we applied a separate multivariable hierarchical generalized linear model (HGLM) with a logit link and binomial distribution to

examine the adjusted association between a patient's HRR quintile (in terms of risk-standardized per patient Medicare expenditure on breast cancer care) and survival. This patient-level HGLM model adjusted for patient sociodemographic and clinical characteristics and accounted for clustering of patients by HRR. HRR quintile was the key explanatory variable and was included in each model. Other patient characteristics were considered as candidate explanatory variables and only those that were significant at the $P < .10$ level in multivariable analysis were retained in final model.

To assess the potential role of treatment factors in mediating the relationship of HRR expenditure quintile and patients' tumor characteristics with survival, we estimated an incremental regression model for 3-year survival and 5-year survival, respectively, by further adjusting for patients' use of surgery, radiation therapy, and systemic therapy. In addition, we conducted separate analysis for women with stage II and stage III breast cancer to examine potential differences in the relationship between HRR quintile and survival by cancer stage. We also evaluated possible effect of treatment modalities in moderating the association between tumor characteristics and survival by estimating interaction terms between treatment indicators and tumor characteristics. As no meaningful interaction effects were identified, we only presented results related to main effects.

To help illustrate our findings, we also calculated risk-standardized 5-year survival rates for each HRR and constructed a scatter plot for the relationship between risk-standardized expenditures and survival rates across the HRRs. Risk-standardized 5-year survival rates were calculated based on risk-adjustment models similar to the HGLM model described above but after removing variables measuring the HRR quintiles. We divided the predicted number of patients who survived in a given HRR (accounting for the HRR's random effect) by the expected number of patients who survived (without the HRR's random effect) and then multiplied this ratio by the sample overall survival rate.²¹ Pearson correlation coefficient was estimated to assess HRR-level association between risk-standardized expenditure and survival.

All analyses were performed using SAS 9.4 (SAS Institute Inc., Cary, NC). All statistical tests were 2-sided and p values less than 0.05 were considered statistically significant.

Results

Sample Characteristics

Our sample included 12,610 women with stage II–III breast cancer residing in 85 HRRs with a mean age of 76.8 years (standard deviation = 6.7). In this cohort, 76.2% of patients had stage II disease and 23.8% were diagnosed with stage III disease (Table 1). Most patients had hormone receptor positive breast cancer (76.0%) and tumors larger than 2 centimeters (78.6%).

Association of Regional Risk-Standardized Expenditures with Survival

The average risk-standardized Medicare expenditure on initial breast cancer care was \$19,597 per patient across the 85 HRRs, but varied from \$13,338 to \$26,831 suggesting a two-fold difference in resource utilization across the HRRs (Figure 1A). Use of major

treatment modalities also varied across HRR expenditure quintiles (Table 2). In general, HRRs in higher-expenditure quintiles had a greater proportion of patients undergoing lumpectomy (rather than mastectomy) or receiving radiation and systemic therapy.

Unadjusted 3-year and 5-year survival in our overall sample was 81.3% and 69.0%, respectively. Across the HRRs, 3-year survival ranged from 66.7% to 92.2% and 5-year survival varied from 50.0% to 84.0%. However, survival did not differ significantly by the HRR expenditure quintiles. Survival at 3 years was 79.6%, 80.2%, 82.0%, 82.3% and 81.2% among patients in HRR quintiles 1–5, respectively ($P=.08$; Table 1), while survival at 5 years was 67.4%, 68.8%, 70.3%, 69.2% and 68.2% in quintiles 1–5, respectively ($P=.28$; Table 1). Kaplan-Meier curves also suggested similar survival patterns across the HRR quintiles (Figure 1B).

After adjusting for patient sociodemographic and clinical characteristics, there was no significant difference in the odds of survival between patients in the lowest-expenditure quintile regions and those in any of the higher-expenditure quintiles. Specifically, the odds ratios of 3-year survival were 1.05 (95% confidence interval [CI]: 0.86–1.28), 1.18 (95% CI: 0.97–1.44), 1.18 (95% CI: 0.97–1.43), and 1.09 (95% CI: 0.88–1.34), respectively, for quintiles 2–5 relative to quintile 1 (overall $P=.35$) (Table 3). Further adjusting for treatment factors generated similar results where the adjusted odds ratios ranged from 1.07 to 1.18 for quintiles 2–5 compared with quintile 1 (overall $P=.44$). The association between other patient characteristics (e.g., tumor characteristics) and survival remained largely unchanged as well.

Likewise, we did not observe a statistically significant association between regional expenditure quintile and 5-year survival (Table 3). Adjusted odds ratios were 1.15 (95% CI: 0.97–1.36), 1.19 (95% CI: 1.01–1.41), 1.10 (95% CI: 0.93–1.30), and 1.03 (95% CI: 0.86–1.24), respectively, for 5-year survival at the 4 higher expenditure quintiles relative to quintile 1 (overall $P=.20$). Further adjustment for treatment factors did not change these results or the association between other patient characteristics and survival. Separate analyses of patients with stage II and stage III breast cancer produced similar results (Supplemental Digital Content 1).

When data were analyzed at the regional level, the results were consistent in that there was no statistically significant association between regional-level breast cancer expenditures and regional-level survival outcomes. Figure 2 illustrates the distribution of risk-standardized 5-year survival rates according to risk-standardized expenditures on breast cancer care across the 85 HRRs. Pearson correlation coefficient between risk-standardized expenditures and risk-standardized 5-year survival rate was -0.006 ($P=.95$). There was substantial variation in the expenditure-survival profile across the HRRs. Twenty-one HRRs (24.7%) attained “high-value” care (upper left quadrant of Figure 2; lower than median expenditure and higher than median survival), while 22 HRRs (25.9%) provided “low-value” care (lower right quadrant of Figure 2; higher than median expenditure and lower than median survival).

Discussion

We found that women who resided in areas with higher breast cancer expenditures were no more likely to survive than their counterparts in lower-spending regions. Similarly, our regional level analysis showed that risk-standardized expenditure was not correlated with HRR risk-standardized survival rate. Notably, there was substantial variation in value of care (i.e., survival outcomes relative to medical expenditures) provided in different HRRs.

Methodologically, our study improves upon previous research assessing the relationship between intensity of resource utilization and outcomes of care in patients with breast cancer. Two studies on breast cancer care have documented no significant association between medical spending and survival.^{8,9} However, both studies relied on total per-patient expenditure (rather than isolating cancer-specific expenditure), and analyzed samples of patients whose outcomes were less amenable to differences in intensity of care (i.e., women with stage IV breast cancer or a high proportion of women with stage 0–I breast cancer).^{8,9} Therefore, their results could be confounded by regional variation in non-cancer care expenses and might underestimate the association between expenditure and survival given the particularly low and high survival rates in these patients (i.e., 5-year relative survival = 22% for stage IV and 100% for stage I).^{1,15} In contrast, we analyzed expenditures specifically on breast cancer care and studied women with stage II–III disease, the group in which treatment intensity would most likely impact survival.

Nevertheless, our study also showed no significant difference in patient survival across the HRR quintiles, despite their large difference in expenditures. Risk-standardized per patient Medicare expenditure on the initial phase of breast cancer care differed by \$13,493 between the lowest- and highest-spending HRRs (\$13,338 versus \$26,831). This magnitude of difference is equivalent to a substantial proportion of annual cost of initial care for many common cancer types (e.g., \$21,412 per elderly female patient with bladder cancer and \$33,167 per elderly female patient with leukemia).²² The lack of association between Medicare spending and patient survival observed in our study is consistent with the growing literature documenting marked variation in costs of care, including cancer care, where high-cost regions did not attain health benefits.^{23–26} These findings suggest opportunities for reducing resource use in high-expenditure regions without compromising patient outcomes.

Efforts to reduce costs in high-spending areas can benefit from more research on causes of geographic variation in costs. Previous research showed that conventional measures of patient and treatment factors (e.g., receipt of chemotherapy, type of radiation therapy) only explained a small proportion of the variation in Medicare expenditure on breast cancer care across HRR,⁶ calling for additional research on other factors that may contribute to the large differences in costs of breast cancer care. Moreover, not all additional utilization of services in high-spending regions is necessarily wasted.²⁷ Research on other cancer types suggests that utilization of both recommended and non-recommended services were higher at high-spending areas.²⁵ Similar studies in breast cancer care with in-depth comparison of practice patterns between high- and low-spending regions are warranted to inform cost-containment strategies that can better target sources of inefficiency (e.g., use of ineffective or non-

recommended services), rather than across-the-board restriction on resource use which may have unintended consequences on quality of care.

Moreover, we found substantial variation in the expenditure-survival profile across HRRs. Some HRRs demonstrated low expenditure-high survival, indicating high-value care, whereas others had poor survival rates even though they also had low expenditures. These results underscore the importance of considering costs in conjunction with patient outcomes, rather than focusing on cost reduction alone. Heterogeneity in these expenditure-survival patterns also offers a unique opportunity to identify exemplary practices at high-value regions. Learning from “positive deviants” in health care, i.e., institutions that exhibit high performance, has been a demonstrated approach to improve care for a variety of health problems.^{28,29} A similar approach can be used in future breast cancer care research to help understand geographic variation in value of care and discern successful practices that may lead to low expenditure and high survival.

Our findings should be interpreted with several limitations in mind. First, as an observational study, we cannot infer any causal relationship between medical expenditures and patient outcomes. However, the results still provide meaningful insight to inform “value” in breast cancer care. Second, as our sample was limited to elderly Medicare patients living in SEER regions which are not nationally representative, our results may not be generalizable to younger patients or to other areas of the country. Third, the Medicare expenditure measure used in our analysis did not include payments from other insurers, patient out-of-pocket expenses, or expenditures from Part D claims such as hormone therapy.⁶ Future research capturing these expenditure components will provide additional insights and may be better able to detect potential differences in survival across geographic regions with different spending. Nevertheless, for most elderly Medicare beneficiaries, Medicare is the primary payer³⁰ and hence incurs most of the expenditures. Moreover, HRRs with higher overall expenditures have been shown to have higher expenditures on components of care as well (e.g., radiation therapy, systemic therapy).⁶ Therefore, variation in Medicare expenditure on breast cancer care captured in our study should reasonably reflect major differences in resource utilization across HRRs. Fourth, we used diagnosis and procedure codes in claims data to identify comorbidities and treatment types which may not accurately capture all detailed clinical information. However, use of claims data allowed us to evaluate the expenditure-survival relationship in a broad population of elderly cancer patients. Finally, our analysis focused on survival and did not examine patient-centered outcomes such as quality of life and other psychosocial outcomes that may be important to cancer patients.³¹ Likewise, we measured 3-year and 5-year survival, which cannot fully capture the impact of recurrent disease or metastases that may arise years later. Further studies assessing these additional aspects of patient outcomes in relationship to resource utilization will provide additional insights.

Conclusions

Our study found that among patients with stage II–III breast cancer, survival was not different between those in high-expenditure versus low-expenditure HRRs. This finding suggests potential opportunities to reduce costs in regions with high spending on breast

cancer care without jeopardizing patient outcomes. It also calls for additional research to identify sources of inefficiency in high-spending regions in order to best inform strategies for containing costs while preserving quality of care.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Funding/Support: This work was supported by the National Cancer Institute at the National Institutes of Health (grant number R01CA149045, PI: Cary Gross). Funder had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

The collection of the California cancer incidence data used in this study was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885; the National Cancer Institute's Surveillance, Epidemiology and End Results Program under contract N01-PC-35136 awarded to the Northern California Cancer Center, contract N01-PC-35139 awarded to the University of Southern California, and contract N02-PC-15105 awarded to the Public Health Institute; and the Centers for Disease Control and Prevention's National Program of Cancer Registries, under agreement #U55/CCR921930-02 awarded to the Public Health Institute. The ideas and opinions expressed herein are those of the author(s) and endorsement by the State of California, Department of Public Health the National Cancer Institute, and the Centers for Disease Control and Prevention or their Contractors and Subcontractors is not intended nor should be inferred. The authors acknowledge the efforts of the Applied Research Program, NCI; the Office of Research, Development and Information, CMS; Information Management Services (IMS), Inc.; and the Surveillance, Epidemiology, and End Results (SEER) Program tumor registries in the creation of the SEER-Medicare database. The interpretation and reporting of the SEER-Medicare data are the sole responsibility of the authors.

References

1. Howlader, N., Noone, AM., Krapcho, M., et al. SEER Cancer Statistics Review, 1975–2013. Bethesda, MD: National Cancer Institute; 2016.
2. Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010–2020. *J Natl Cancer Inst.* 2011; 103:117–128. [PubMed: 21228314]
3. Feinstein AJ, Long J, Soulos PR, et al. Older women with localized breast cancer: costs and survival rates increased across two time periods. *Health Aff (Millwood).* 2015; 34:592–600. [PubMed: 25847641]
4. Howard DH, Chernew ME, Abdelgawad T, et al. New anticancer drugs associated with large increases in costs and life expectancy. *Health Aff (Millwood).* 2016; 35:1581–1587. [PubMed: 27605636]
5. Philipson T, Eber M, Lakdawalla DN, et al. An analysis of whether higher health care spending in the United States versus Europe is 'worth it' in the case of cancer. *Health Aff (Millwood).* 2012; 31:667–675. [PubMed: 22492882]
6. Xu X, Herrin J, Soulos PR, et al. The role of patient factors, cancer characteristics, and treatment patterns in the cost of care for Medicare beneficiaries with breast cancer. *Health Serv Res.* 2016; 51:167–186. [PubMed: 26119176]
7. Paravati AJ, Boero IJ, Triplett DP, et al. Variation in the cost of radiation therapy among Medicare patients with cancer. *J Oncol Pract.* 2015; 11:403–409. [PubMed: 26265172]
8. Brooks GA, Li L, Sharma DB, et al. Regional variation in spending and survival for older adults with advanced cancer. *J Natl Cancer Inst.* 2013; 105:634–642. [PubMed: 23482657]
9. Hassett MJ, Neville BA, Weeks JC. The relationship between quality, spending and outcomes among women with breast cancer. *J Natl Cancer Inst.* 2014; 106:dju242. [PubMed: 25217776]

10. Feinstein AJ, Soulos PR, Long JB, et al. Variation in receipt of radiation therapy after breast-conserving surgery: assessing the impact of physicians and geographic regions. *Med Care*. 2013; 51:330–338. [PubMed: 23151590]
11. Nattinger AB, Gottlieb MS, Veum J, et al. Geographic variation in the use of breast-conserving treatment for breast cancer. *N Engl J Med*. 1992; 326:1102–1107. [PubMed: 1552911]
12. National Cancer Institute. [Accessed October 10, 2016] Overview of the SEER Program. Available at: <http://seer.cancer.gov/about/overview.html>
13. Beebe-Dimmer JL, Fryzek JP, Yee CL, Dalvi TB, Garabrant DH, Schwartz AG, Gadageel S. Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)-Medicare investigation of treatment patterns and overall survival. *Clin Epidemiol*. 2016; 26:743–750.
14. National Cancer Institute. [Accessed July 18, 2017] Surveillance, Epidemiology, and End Results Program. About the SEER Registries. Available at: <https://seer.cancer.gov/registries/>
15. American Cancer Society. [Accessed October 10, 2016] Breast cancer survival rates, by stage. Available at: <http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-survival-by-stage>
16. Yasmeen S, Hubbard RA, Romano PS, et al. Risk of advanced-stage breast cancer among older women with comorbidities. *Cancer Epidemiol Biomarkers Prev*. 2012; 21:1510–1519. [PubMed: 22744339]
17. Dartmouth Atlas of Health Care. Downloads, Crosswalks, Zip Code Crosswalks 1995–2010. Lebanon, NH: The Dartmouth Institute for Health Policy and Clinical Practice; 2011.
18. Dartmouth Atlas of Health Care. [Accessed February 20, 2017] Research Methods. Available at: http://www.dartmouthatlas.org/downloads/methods/research_methods.pdf
19. Elixhauser A, Steiner C, Harris DR, et al. Comorbidity measures for use with administrative data. *Med Care*. 1998; 36:8–27. [PubMed: 9431328]
20. Davidoff AJ, Zuckerman IH, Pandya N, et al. A novel approach to improve health status measurement in observational claims-based studies of cancer treatment and outcomes. *J Geriatr Oncol*. 2013; 4:157–165. [PubMed: 23795223]
21. Normand S-LT, Glickman ME, Gatsonis CA. Statistical methods for profiling providers of medical care: issues and applications. *J Am Stat Assoc*. 1997; 92:803–814.
22. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010–2020. *J Natl Cancer Inst*. 2011; 103:117–128. [PubMed: 21228314]
23. Hussey PS, Wertheimer S, Mehrotra A. The association between health care quality and cost: a systematic review. *Ann Intern Med*. 2013; 158:27–34. [PubMed: 23277898]
24. Zeidan AM, Wang R, Davidoff AJ, et al. Disease-related costs of care and survival among Medicare-enrolled patients with myelodysplastic syndromes. *Cancer*. 2016; 122:1598–607. [PubMed: 26970288]
25. Landrum MB, Meara ER, Chandra A, et al. Is spending more always wasteful? The appropriateness of care and outcomes among colorectal cancer patients. *Health Aff (Millwood)*. 2008; 27:159–168. [PubMed: 18180491]
26. Skolarus TA, Ye Z, Zhang S, et al. Regional differences in early stage bladder cancer care and outcomes. *Urology*. 2010; 76:391–6. [PubMed: 20394976]
27. Skinner J. Causes and Consequences of Regional Variations in Health Care. In: Pauly, MV, McGuire, TG., Barros, PP., editors. *Handbook of Health Economics*. Waltham, MA: Elsevier; 2011. p. 45–93.
28. Bradley EH, Curry LA, Ramanadhan S, et al. Research in action: using positive deviance to improve quality of health care. *Implement Sci*. 2009; 4:25. [PubMed: 19426507]
29. Marsh DR, Schroeder DG, Dearden KA, et al. The power of positive deviance. *BMJ*. 2004; 329:1177–1179. [PubMed: 15539680]
30. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. *Med Care*. 2002; 40(8 Suppl):IV-3–18.

31. Perry S, Kowalski TL, Chang CH. Quality of life assessment in women with breast cancer: benefits, acceptability and utilization. *Health Qual Life Outcomes*. 2007; 5:24. [PubMed: 17474993]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 1.

Figure 1A. Distribution of Risk-standardized per Patient Medicare Expenditure on Initial Phase of Breast Cancer Care across Hospital Referral Regions (HRRs)

Figure 1B. Kaplan-Meier Curve of Survival over Time across Expenditure Quintiles
Quintiles 1–5 reflect the lowest to highest quintiles of **risk-standardized** Medicare
expenditure on **initial** breast cancer care **among HRRs**.

Figure 2.

Distribution of Risk-Standardized per Patient Medicare Expenditure on **Initial Phase of** Breast Cancer Care and Risk-Standardized 5-year Survival Rate among 85 hospital referral regions

Each dot in the figure reflects a hospital referral region (HRR). The bold lines indicate median risk-standardized per patient Medicare expenditure on **initial** breast cancer care and median risk-standardized survival rate among the 85 HRRs.

Table 1

Sample Characteristics and Bivariate Association with 3-year and 5-year Survival

Patient Characteristic	N	%	Bivariate Association with Survival			
			% surviving 3 years	P-value *	% surviving 5 years	P-value *
HRR quintile of risk-standardized per patient Medicare expenditure on initial breast cancer care						
1 (lowest)	1604	12.7	79.6		67.4	
2	2488	19.7	80.2		68.8	
3	3324	26.4	82.0	.08	70.3	.28
4	3499	27.8	82.3		69.2	
5 (highest)	1695	13.4	81.2		68.2	
Age at diagnosis (years)						
67–69	2109	16.7	90.1		82.7	
70–74	3136	24.9	89.3		80.1	
75–79	3048	24.2	83.5	<.001	71.6	<.001
80–84	2447	19.4	75.4		60.5	
85–94	1870	14.8	62.4		42.2	
Race						
White	11088	87.9	81.5		69.3	
Black	1030	8.2	77.4	<.001	62.4	<.001
Other	492	3.9	86.0		77.2	
Marital status						
Married	5046	40.0	87.2		77.7	
Not married	7096	56.3	77.1	<.001	63.1	<.001
Unknown	468	3.7	82.5		66.5	
Median household income						
<\$33,000	2778	22.0	78.9		65.4	
\$33,000–\$39,999	1881	14.9	79.5		67.0	
\$40,000–\$49,999	2684	21.3	80.6	<.001	66.9	<.001
\$50,000–\$62,999	2392	19.0	82.8		70.5	
\$63,000	2875	22.8	84.3		74.6	
Metropolitan area residence						

Patient Characteristic	N	%	Bivariate Association with Survival		
			% surviving 3 years	P-value *	% surviving 5 years
Yes	10470	83.0	81.9		69.7
No	2140	17.0	78.7	<.001	65.9
Year of diagnosis					
2005	3276	26.0	80.2		67.8
2006	3181	25.2	80.3		68.5
2007	3167	25.1	81.8	.006	69.5
2008	2986	23.7	83.2		70.5
Comorbidity score					
0	5478	43.4	88.1		78.7
1-2	4838	38.4	81.4	<.001	68.5
3	2294	18.2	65.0		47.1
Disability status					
Not disabled	11177	88.6	84.4		72.9
Disabled	1433	11.4	57.0	<.001	38.9
Prior receipt of flu shot					
No	5273	41.8	80.8		67.8
Yes	7337	58.2	81.7	.22	70.0
Prior PCP visit					
No	804	6.4	77.4		64.3
Yes	11806	93.6	81.6	.003	69.4
Cancer stage					
II	9612	76.2	84.9		73.9
III	2998	23.8	69.9	<.001	53.5
Tumor size (cm)					
<2	2488	19.7	91.0		82.5
2-5	8470	67.2	81.4		68.6
>5	1436	11.4	66.2	<.001	50.7
Unknown	216	1.7	68.1		54.6
Laterality					
Right-sided	6204	49.2	81.8	.21	69.3
					.57

Patient Characteristic	N	%	Bivariate Association with Survival		
			% surviving 3 years	P-value *	% surviving 5 years
Left-sided	6406	50.8	80.9		68.8
Positive node(s)					
No	5425	43.0	81.6		69.8
Yes	7185	57.0	81.1	.43	68.5
Hormone receptor status					
Negative	2291	18.2	69.8		57.4
Positive	9580	76.0	84.6	<.001	72.4
Unknown	739	5.9	74.4		61.6
Tumor grade					
1	1876	14.9	88.5		78.9
2	5388	42.7	84.9		72.5
3	4571	36.3	74.7	<.001	61.7
4	146	1.2	71.2		57.5
Unknown	629	5.0	79.7		65.5
Type of surgery					
Lumpectomy	5234	41.5	86.6		76.3
Mastectomy	7376	58.5	77.6	<.001	63.9
Receipt of radiation therapy					
No	6454	51.2	74.7		60.3
Yes	6156	48.8	88.3	<.001	78.2
Receipt of chemotherapy					
No	7960	63.1	78.6		65.0
Yes	4650	36.9	85.9	<.001	76.0

Abbreviations: HRR, hospital referral region; PCP, primary care physician.

* P-value based on Chi-square test of the association between each covariate and survival

Table 2

Use of breast cancer treatment across quintiles of hospital referral regions (HRRs)

Treatment	HRR quintile of risk-standardized per patient Medicare expenditure on initial breast cancer care				
	1 (lowest)	2	3	4	5 (highest)
Surgery					
Lumpectomy	38.2%	35.7%	45.5%	43.6%	41.1%
Mastectomy	61.9%	64.3%	54.5%	56.4%	58.9%
Radiation therapy	46.6%	44.5%	50.9%	51.1%	48.6%
Systemic therapy	34.5%	36.7%	35.8%	38.2%	39.7%

Table 3

Adjusted Association of Patient Characteristics with 3-year and 5-year Survival

Patient Characteristic	3-year Survival*			5-year Survival*		
	Without Adjustment for Treatment Factors		With Adjustment for Treatment Factors	Without Adjustment for Treatment Factors		With Adjustment for Treatment Factors
	Adjusted OR (95% CI)	P-value	Adjusted OR (95% CI)	Adjusted OR (95% CI)	P-value	Adjusted OR (95% CI)
HRR quintile of risk-standardized per patient Medicare expenditure on initial breast cancer care						
1 (lowest)	Reference		Reference	Reference		Reference
2	1.05 (0.86,1.28)		1.07 (0.88,1.30)	1.15 (0.97,1.36)		1.16 (0.98,1.38)
3	1.18 (0.97,1.44)	.35	1.18 (0.97,1.42)	1.19 (1.01,1.41)	.20	1.18 (0.998,1.39)
4	1.18 (0.97,1.43)		1.16 (0.96,1.40)	1.10 (0.93,1.30)		1.08 (0.91,1.27)
5 (highest)	1.09 (0.88,1.34)		1.07 (0.87,1.32)	1.03 (0.86,1.24)		1.01 (0.84,1.21)
Age at diagnosis (years)						
67–69	Reference		Reference	Reference		Reference
70–74	0.95 (0.78,1.15)		0.99 (0.82,1.20)	0.87 (0.74,1.01)		0.90 (0.77,1.05)
75–79	0.61 (0.51,0.74)	<.001	0.69 (0.57,0.83)	0.57 (0.49,0.66)	<.001	0.63 (0.54,0.74)
80–84	0.39 (0.33,0.47)		0.48 (0.40,0.58)	0.36 (0.31,0.42)		0.44 (0.38,0.52)
85–94	0.22 (0.18,0.27)		0.30 (0.24,0.37)	0.18 (0.15,0.21)		0.23 (0.20,0.28)
Race						
White	NA [†]		NA [†]	Reference		Reference
Black	NA [†]		NA [†]	1.02 (0.87,1.20)	.07	1.00 (0.85,1.18)
Other	NA [†]		NA [†]	1.33 (1.05,1.69)		1.37 (1.08,1.75)
Marital status						
Married	Reference		Reference	Reference		Reference
Not married	0.81 (0.72,0.91)	<.001	0.84 (0.75,0.95)	0.81 (0.73,0.89)	<.001	0.83 (0.76,0.92)
Unknown	1.04 (0.79,1.37)		1.11 (0.84,1.48)	0.82 (0.65,1.03)		0.86 (0.68,1.09)
Median household income						
<\$33,000	NA [†]		NA [†]	Reference	.004	Reference

Patient Characteristic	3-year Survival*				5-year Survival*			
	Without Adjustment for Treatment Factors		With Adjustment for Treatment Factors		Without Adjustment for Treatment Factors		With Adjustment for Treatment Factors	
	Adjusted OR (95% CI)	P-value	Adjusted OR (95% CI)	P-value	Adjusted OR (95% CI)	P-value	Adjusted OR (95% CI)	P-value
\$33,000–\$39,999	NA [†]		NA [†]		0.95 (0.83,1.10)		0.95 (0.82,1.10)	
\$40,000–\$49,999	NA [†]		NA [†]		0.89 (0.78,1.02)		0.88 (0.76,1.01)	
\$50,000–\$62,999	NA [†]		NA [†]		1.00 (0.86,1.16)		0.97 (0.83,1.12)	
\$63,000	NA [†]		NA [†]		1.16 (1.00,1.34)		1.12 (0.96,1.30)	
Metropolitan area residence								
Yes	Reference		Reference		Reference		Reference	
No	0.85 (0.74,0.98)	.02	0.89 (0.77,1.02)	.09	0.87 (0.76,0.99)	.04	0.90 (0.79,1.03)	.11
Comorbidity score								
0	Reference		Reference		Reference		Reference	
1–2	0.64 (0.57,0.73)	<.001	0.67 (0.59,0.76)	<.001	0.62 (0.56,0.69)	<.001	0.65 (0.58,0.71)	<.001
3	0.32 (0.28,0.36)		0.34 (0.30,0.39)		0.29 (0.26,0.33)		0.31 (0.27,0.35)	
Disability status								
Not disabled	Reference		Reference		Reference		Reference	
Disabled	0.46 (0.40,0.52)	<.001	0.52 (0.45,0.60)	<.001	0.45 (0.39,0.51)	<.001	0.50 (0.44,0.57)	<.001
Prior receipt of flu shot								
No	NA [†]		NA [†]		Reference		Reference	
Yes	NA [†]		NA [†]		1.13 (1.03,1.24)	.008	1.09 (1.00,1.20)	.06
Prior PCP visit								
No	Reference		Reference		Reference		Reference	
Yes	1.19 (0.97,1.47)	.10	1.09 (0.88,1.34)	.43	1.23 (1.02,1.48)	.03	1.14 (0.94,1.37)	.18
Cancer Stage								
II	Reference		Reference		Reference		Reference	
III	0.50 (0.44,0.56)	<.001	0.42 (0.37,0.47)	<.001	0.45 (0.40,0.50)	<.001	0.37 (0.33,0.42)	<.001
Tumor size (cm)								
<2	Reference		Reference		Reference		Reference	
2–5	0.61 (0.52,0.72)	<.001	0.65 (0.55,0.76)	<.001	0.63 (0.56,0.72)	<.001	0.66 (0.59,0.75)	<.001

Patient Characteristic	3-year Survival*			5-year Survival*		
	Without Adjustment for Treatment Factors		With Adjustment for Treatment Factors	Without Adjustment for Treatment Factors		With Adjustment for Treatment Factors
	Adjusted OR (95% CI)	P-value	Adjusted OR (95% CI)	Adjusted OR (95% CI)	P-value	Adjusted OR (95% CI)
>5	0.39 (0.32,0.47)		0.40 (0.33,0.50)	0.44 (0.37,0.52)		0.45 (0.38,0.54)
Unknown	0.38 (0.27,0.54)		0.38 (0.26,0.54)	0.47 (0.34,0.65)		0.47 (0.34,0.65)
Hormone receptor status						
Negative	Reference		Reference	Reference		Reference
Positive	2.04 (1.80,2.32)	<.001	2.20 (1.93,2.51)	1.72 (1.53,1.93)	<.001	1.84 (1.64,2.08)
Unknown	1.38 (1.12,1.72)		1.59 (1.28,1.98)	1.34 (1.10,1.64)		1.53 (1.26,1.87)
Tumor grade						
1	Reference		Reference	Reference		Reference
2	0.83 (0.70,0.99)		0.82 (0.69,0.98)	0.77 (0.67,0.88)		0.76 (0.66,0.87)
3	0.58 (0.49,0.69)	<.001	0.56 (0.47,0.67)	0.59 (0.51,0.68)	<.001	0.56 (0.48,0.65)
4	0.50 (0.33,0.78)		0.51 (0.33,0.79)	0.49 (0.33,0.72)		0.48 (0.32,0.72)
Unknown	0.75 (0.58,0.98)		0.74 (0.57,0.97)	0.68 (0.54,0.85)		0.67 (0.53,0.84)
Type of surgery						
Lumpectomy			Reference			Reference
Mastectomy			1.06 (0.94,1.20)		.37	1.04 (0.94,1.16)
Receipt of radiation therapy						
No			Reference			Reference
Yes			2.00 (1.77,2.25)		<.001	1.86 (1.67,2.06)
Receipt of systemic therapy						
No			Reference			Reference
Yes			1.32 (1.15,1.51)		<.001	1.33 (1.19,1.49)

Abbreviations: CI, confidence interval; HRR, hospital referral region; OR, odds ratio; PCP, primary care physician.

* Model also adjusted for year of diagnosis.

[†]NA = not applicable (covariate not included in final regression model because it was not statistically significant at p<.10 level)